2023 Annual Meeting | Industry Therapeutic Update from Azurity Pharmaceuticals: Restless Legs Syndrome Updated Guidelines and Management Strategies for Improved Patient Outcomes

Date Tuesday 04/25/23

Time 06:00 PM - 09:00 PM EST Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) John Winkelman, MD, PhD

Topic(s) General Neurology, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-rehabilitation

Learning Objectives Dr. Winkelman will describe revised treatment guidelines from the Restless Legs Syndrome Foundation which, based on recent evidence related to both efficacy and safety, describe a paradigm shift in the treatment of Restless Legs Syndrome (RLS). It is now recommended that dopaminergic agents (DAs) should no longer be first-line treatments for chronic persistent RLS due to their propensity to worsen RLS symptoms over time (augmentation). Rather, calcium channel α2δ ligands (A2Ds) or iron (in those with appropriate iron indices) are now considered initial treatments. He will also review the diagnostic criteria for RLS, the FDA-approved medications for RLS, and the features of dopaminergic augmentation of RLS. Dr. Winkelman will conclude with a Q&A session to give attendees the opportunity to ask questions.

Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2023 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Event Timeline
06:00 PM - 09:00 PM EST	Speaker	Industry Therapeutic Update from Azurity Pharmaceuticals: Restless Legs Syndrome Updated Guidelines and Management Strategies for Improved Patient Outcomes

Faculty Disclosures
John Winkelman, MD, PhD	John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexza. John Winkelman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Azurity. John Winkelman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Disc Medicine. An immediate family member of John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Emalex. John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentec. John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Haleon. John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. John Winkelman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Noctrix. John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Psychogenics. The institution of John Winkelman has received research support from American Regent. The institution of John Winkelman has received research support from Merck. John Winkelman has received publishing royalties from a publication relating to health care. John Winkelman has a non-compensated relationship as a Chair with International Restless Legs Syndrome Study Group that is relevant to AAN interests or activities. John Winkelman has a non-compensated relationship as a Member with Restless Legs Syndrome Foundation Scientific Medical Advisory Board that is relevant to AAN interests or activities.

��ɫ��

��ɫ��